+1,954.6%
ALNY vs GSK
+227.3%
+1,727.3%
-83.6%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for all.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | -2.7% | -0.1% | -2.6% | -2.6% |
| 7D | -12.9% | -5.3% | -7.5% | -10.2% |
| 30D | -36.1% | -3.7% | -32.5% | -35.0% |
| 3M | -37.3% | -7.3% | -30.0% | -34.9% |
| 6M | -51.8% | -4.2% | -47.6% | -50.7% |
| YTD | -63.8% | +0.9% | -64.7% | -64.3% |
| 1Y | -67.7% | +7.3% | -75.0% | -69.2% |
| 3Y | -13.0% | +52.7% | -65.7% | -34.5% |
| 5Y | -20.5% | +40.1% | -60.7% | -39.6% |
| 10Y | +212.8% | +98.7% | +114.1% | +76.1% |
| All | +1,954.6% | +227.3% | +1,727.3% | +807.5% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over all: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
all analysis · Full analysis span regression · 6 months rolling